Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use.

This regulatory decision makes IGALMI the first FDA-approved treatment that adults can use at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

IGALMI (dexmedetomidine) sublingual film is a prescription medicine that is placed under the tongue or between the lower lip and gum and is used for the treatment of sudden (acute) agitation in adults with schizophrenia, schizoaffective disorder, or bipolar disorder I or II.

Phase 3 Trial Confirms Consistent Tolerability

During the 12-week Phase 3 SERENITY At-Home Safety and Tolerability Trial, investigators treated 1,160 agitation episodes across 102 patients with IGALMI.

Patients maintained consistent tolerability with repeat dosing throughout the study period, and zero participants discontinued treatment due to tolerability concerns.

The most frequent adverse events—occurring in at least 5% of patients and exceeding placebo rates—included somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia.

BioXcel Asset Deal And Regulatory Path

Teva acquired IGALMI in late October 2026 from BioXcel Therapeutics, Inc., securing worldwide rights to the investigational sublingual film, previously known as BXCL501.

The company paid $57.5 million upfront and agreed to provide up to $67.5 million in contingent payments.

TEVA Price Action: Teva Pharmaceutical Indus shares were down 2.40% at $43.43 at the time of publication on Monday. The stock is approaching its 52-week high of $44.56, according to Benzinga Pro data.

Photo: Shutterstock